| Literature DB >> 6345174 |
A Ahre, M Björkholm, H Mellstedt, G Holm, G Brenning, L Engstedt, G Gahrton, J Hällen, B Johansson, S G Johansson, L Karnström, A Killander, R Lerner, D Lockner, B Lönnqvist, B Simonsson, A M Stalfelt, B Ternstedt, B Wadman.
Abstract
Patients with newly diagnosed multiple myeloma were randomly allotted to an intermittent high-dose melphalan/prednisone (MP) treatment (120 patients) or a continuous low-dose melphalan (M) regimen (99 patients). The median observation time was 59 months (range 33-84). Response to therapy was obtained in 45% of the MP group and 31% of the M group (P less than 0.05). No significant difference in response with regard to clinical stage was noted. Median survival was 36 months in the MP group and 29 months in the M group. Survival was longer in stage I and II myeloma than in the stage III cases, at least in the MP group. The median and 5-yr survival rates in stages I and II were significantly better in the MP than in the M group. Response to therapy was associated with length of survival, median survival being 62 months in responding patients and 20 months in non-responders. The MP and M groups did not differ in this respect.Entities:
Mesh：
Substances：
Year: 1983 PMID： 6345174 DOI： 10.1016/0277-5379(83)90113-x
Source DB: PubMed Journal: Eur J Cancer Clin Oncol ISSN： 0277-5379